Salaheldin S Hamed - Center for Drug Evaluation and Research (CDER), US Food and Drug Administration

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 17 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Supplementary Table S4 from FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

William F. Maguire,Daniel Lee,Chana Weinstock,Xin Gao,Catharine C. Bulik,Sundeep Agrawal,Elaine Chang,Salaheldin S. Hamed,Erik W. Bloomquist,Shenghui Tang,Richard Pazdur,Paul G. Kluetz,Laleh Amiri-Kordestani,Daniel L. Suzman

crossref（2024）

引用0浏览0引用

Supplementary Figure S1 from FDA Approval Summary: Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

crossref（2024）

引用0浏览0引用

Supplementary Figure S2 from FDA Approval Summary: Enfortumab Vedotin Plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

crossref（2024）

引用0浏览0引用

FDA Approval Summary: Olaparib in Combination with Abiraterone for Treatment of Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Jaleh Fallah,Jianjin Xu,Chana Weinstock,Michael H. Brave,Erik Bloomquist,Mallorie H. Fiero, Timothy Schaefer,Anand Pathak, Abdelrahmman Abukhdeir,Vishal Bhatnagar,Haw-Jyh Chiu,Tiffany Ricks, Christy John,Salaheldin Hamed, Christal Lee,William F. Pierce,Shyam Kalavar,Reena Philip,Shenghui Tang,Laleh Amiri-Kordestani,Richard Pazdur,Paul G. Kluetz,Daniel Suzman

JOURNAL OF CLINICAL ONCOLOGYno. 5 (2024)

引用0浏览0WOS引用

US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

Mirat Shah, Hima Lingam, Xin Gao,Haley Gittleman,Mallorie H. Fiero,Danielle Krol, Nikolett Biel,Tiffany K. Ricks,Wentao Fu,Salaheldin Hamed, Fang Li, Jillian (Jielin) Sun,Jianghong Fan,Robert Schuck,Manuela Grimstein, Liuya Tang,Shyam Kalavar, Abdelrahmman Abukhdeir,Anand Pathak,Soma Ghosh,Ilynn Bulatao,Amy Tilley,William F. Pierce,Bronwyn D. Mixter,Shenghui Tang,Richard Pazdur,Paul Kluetz,Laleh Amiri-Kordestani

JOURNAL OF CLINICAL ONCOLOGYno. 10 (2024)

引用0浏览0WOS引用

Supplementary Table S3 from FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

crossref（2024）

引用0浏览0引用

Supplementary Table S5 from FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

crossref（2024）

引用0浏览0引用

Supplementary Table S1 from FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

William F. Maguire, Daniel Lee,Chana Weinstock,Xin Gao,Catharine C. Bulik,Sundeep Agrawal,Elaine Chang,Salaheldin S. Hamed,Erik W. Bloomquist,Shenghui Tang,Richard Pazdur,Paul G. Kluetz,Laleh Amiri-Kordestani,Daniel L. Suzman

crossref（2024）

引用0浏览0引用

Supplementary Table S2 from FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

William F. Maguire, Daniel Lee,Chana Weinstock, Xin Gao,Catharine C. Bulik,Sundeep Agrawal,Elaine Chang,Salaheldin S. Hamed,Erik W. Bloomquist,Shenghui Tang,Richard Pazdur,Paul G. Kluetz,Laleh Amiri-Kordestani,Daniel L. Suzman

crossref（2024）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn